首页 | 本学科首页   官方微博 | 高级检索  
     

组织激肽释放酶在糖尿病视网膜病变患者血清中的变化及其调节血管新生机制
引用本文:赵吉飞,杜建英,刘彦章,侯力华. 组织激肽释放酶在糖尿病视网膜病变患者血清中的变化及其调节血管新生机制[J]. 眼科新进展, 2016, 0(9): 844-848. DOI: 10.13389/j.cnki.rao.2016.0226
作者姓名:赵吉飞  杜建英  刘彦章  侯力华
作者单位:712000 陕西省咸阳市,咸阳市第一人民医院眼一科
摘    要:目的 检测组织激肽释放酶(tissuekallikrein,TKLK)、血管内皮细胞生长因子(vascularendothelialgrowthfactor,VEGF)和可溶性细胞间黏附分子-1(solubleintracellularadhensionmolecul-1,sICAM-1)在糖尿病视网膜病变(diabeticretinopathy,DR)患者血清中的变化,观察TKLK在低氧条件下对人视网膜微血管内皮细胞(humanretinalmicrovascularendothelialcells,HRMECs)中VEGF和ICAM-1表达的影响。方法 收集2型糖尿病患者60例,按照DR分期标准将患者分为糖尿病无DR组(DM组)、非增生性DR组(NPDR组)和增生性DR组(PDR组),收集同期在本院体检的志愿者作为对照组,每组20例。ELISA法检测血清中TKLK、VEGF和sICAM-1的水平。体外HRMECs分别进行常氧和低氧培养,不同浓度重组TKLK处理后,检测细胞增殖、凋亡以及VEGF和ICAM-1的表达。结果 DM、NPDR和PDR组患者血清中TKLK、VEGF和sICAM-1水平明显高于对照组,4组总体差异有统计学意义(F=28.805,P=0.002;F=32.041,P=0.002;F=26.169,P=0.001);PDR患者血清中TKLK、VEGF和sICAM-1水平显著高于DM和NPDR组(均为P<0.001)。TKLK与VEGF(r=0.623,P<0.01)和sICAM-1水平(r=0.598,P<0.01)均呈正相关。10μg?mL-1rhTKLK可显著抑制低氧诱导的HRMECs增殖以及VEGF和ICAM-1的表达,并可促进细胞凋亡(P<0.05)。结论 TKLK通过与VEGF和ICAM-1相互作用而影响DR的进展。

关 键 词:糖尿病视网膜病变  组织激肽释放酶  血管生成  血管内皮细胞生长因子  细胞间黏附分子-1

Changes of tissue kallikrein in serum of patients with diabetic retinopathy and its role in retinal angiogensis
ZHAO Ji-Fei,DU Jian-Ying,LIU Yan-Zhang,HOU Li-Hua. Changes of tissue kallikrein in serum of patients with diabetic retinopathy and its role in retinal angiogensis[J]. Recent Advances in Ophthalmology, 2016, 0(9): 844-848. DOI: 10.13389/j.cnki.rao.2016.0226
Authors:ZHAO Ji-Fei  DU Jian-Ying  LIU Yan-Zhang  HOU Li-Hua
Affiliation:Department of Opthalmology, the First People ’ s Hospital of Xianyang City, Xianyang 712000 , Shaanxi Province , China
Abstract:Objective To determine the levels of serum tissue kallikrein ( TKLK) ,vascular endothelial growth factor ( VEGF) and soluble intracellular adhension molecul-l ( sICAM-I) in diabetic retinopathy ( DR) patients.and evaluate the effects of TKLK on the expression of VEGF and ICAM-I in human retinal vascular endothelial cells ( HRMECs) under hypoxia. Methods Sixty DM patients were enrolled and grouped according to the staging criteria of DR into: DM patients without DR group ( DM group) ,non-proliferative DR group ( NPDR group) and proliferative DR group ( PDR group ) . Simultaneously ,20 healthy volunteers were collected as the controls. ELISA was applied to measure the levels of serum TKLK .VEGF and sICAM-I in all the eligible subjects,and the correlations between them were analyzed. HRMECs were incubated in vitro with various concentrations of thTKLK. and then were grown in normoxia and hypoixa conditions. Cell viability and apoptosis as well as the expression of VEGF and ICAM-I were examined. Results The serum levels of TKLK.VEGF and sICAM-I in DM .NPDR and PDR groups were higher than that in control group , there were significant differences among four groups ( F = 28. 805 .P = 0. 002 ; F = 32. 041 ,P = 0. 002 .F = 26. 169 .P =0. 001 ). Meanwhile , the serum levels of TKLK.VEGF and sICAM-I in PDR group were higher than those in DM and NPDR groups ( all P < 0. 001 ) . There were significant positive correlations between the levels of TKLK and VEGF ( r = 0. 623 ,P < 0. 01 ) as well as TKLK and sICAM-I ( r = 0. 598 .P < 0. 01 ) . 10 Vg . mL -l thTKLK dramatically inhibited the hypoxia-induced proliferation of HRMECs and expression of VEGF and ICAM-I .while significantly promoted cell apoptosis (P < 0. 05 ) . Conclusion TKLK participate in the progression of DR via interaction with VEGF and ICAM-I.
Keywords:diabetic retinopathy  tissue kallikrein  angiogenesis  vascular endothelial growth factor  intracellular adhension molecul-1
本文献已被 万方数据 等数据库收录!
点击此处可从《眼科新进展》浏览原始摘要信息
点击此处可从《眼科新进展》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号